AGM Statement

Jun 12, 2012

Advanced Medical Solutions Group plc
(“AMS” or the “Group”)

RNS Number : 1429F
Advanced Medical Solutions Grp PLC
12 June 2012

12 June 2012


Advanced Medical Solutions Group plc

(“AMS” or the “Group”)


Annual General Meeting and Update on Trading


Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS.L), the global medical technology company, will hold its Annual General Meeting at 11.00 today.


Dr. Don Evans, Non-Executive Chairman of the Group, will make the following statement regarding current trading.


“I am pleased to report that the good start to the year, as highlighted in the 2011 Preliminary Results announcement on 7 March 2012, is continuing.


We continue to make good progress in the US market with our LiquiBand® range of products, with end-user sales increasing and further market share gains. We expect to see the impact of this progress in our ex-factory sales during the second half and we anticipate good growth for the full year. In relation to LiquiBand Flex®, we are well advanced with signing up and training distributors and are currently going through key evaluations which should be finalised by the end of the summer.


Our integration of RESORBA® is progressing to plan. We are advancing through the programme set out at the beginning of the year and we have now completed the first NHS tender for RESORBA®’s range of products, in line with our stated strategy. We expect the outcome of this first tender toward the end of the year. As a consequence of the RESORBA® acquisition, more of our Group revenues are now Euro denominated. The Group has hedged to protect profitability and, although underlying sales remain healthy, the consequent weakening of the currency could affect our headline revenue number on translation into sterling. 


Elsewhere in the Group, our ActivHeal® range continues to perform well and the de-stocking effect that we experienced with one of our partners for silver alginate is now behind us. In our foam business, the targeted H2 launch of trilaminate foam dressings remains on track. However, as discussed in our Preliminary Results, 2012 foam revenues are expected to be impacted by the non-repetition of a large, roll-stock launch order in 2011, combined with our continuing strategy of focusing on higher margin business.


The effect of the expected reduction in foam revenues, together with the likely Euro impact, is that we anticipate full year Group revenues will be below expectations but with a negligible effect on profitability.


In conclusion, whilst global economic conditions remain challenging, the Board is pleased to confirm that we expect profitability for the full year 2012 to be in line with current market forecasts. The long term prospects for the Group remain excellent and we look forward to the coming months with confidence.”


– ends –


For further information, please visit or contact:


Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Mary Tavener, Group Finance Director

Tavistock Communications

Tel: +44 (0) 20 7920 3150

John West / Chris Munden / Andrew Dunn

Investec Bank plc

Tel: +44 (0) 20 7597 5970

Gary Clarence / Daniel Adams / Patrick Robb


About Advanced Medical Solutions Group plc – see 


Founded in 1991, AMS is a leader in the development and manufacture of innovative and technologically advanced products for the US$15 billion global wound care market. These products are sold in countries across the globe either directly or through strategic partners and distributors.


AMS’s advanced woundcare products are based on an extensive range of technologies including alginates, silver alginates and hydrophilic polyurethane foams. These and other products pioneer the concept of moist wound healing, allowing wounds to heal faster and with less pain and scarring. They protect the wound, deal with tissue fluids, provide an optimal environment for healing to occur and, in the case of silver alginates, include a safe and effective broad-spectrum anti-microbial agent for infection control. AMS’s advanced woundcare products are sold globally on an Original Equipment Manufacturer basis and, in the UK, direct to the NHS under the ActivHeal® brand.


AMS’s wound closure and sealants products are based on cyanoacrylate adhesive (“superglue”) technology developed for medical applications. Tissue adhesives offer significant benefits over conventional ways of closing wounds following trauma or surgical incision. They are simple to use, non-invasive, help to reduce the risk of infection, minimise trauma to the patient and provide good clinical and cosmetic outcomes. The technology is also ideally suited to protecting skin from breakdown or for use as a skin sealant to help prevent infection of surgical sites. AMS’s wound closure and sealants products are primarily sold under the LiquiBand® brand via a network of distributors.


In December 2011, AMS acquired RESORBA, a German based woundcare and wound closure business. RESORBA® is a 75 year old manufacturer and distributor of sutures and collagen products for surgical disciplines, with direct sales capabilities from sites in Germany, the Czech Republic and Russia, targeting surgeons working in hospitals and private practices, and oral surgery. RESORBA® has a range of its own technologies and brands, and also distributes a range of complementary, third-party products, including AMS’s LiquiBand® tissue adhesive, which it has distributed in Germany for the previous eight years.


This information is provided by RNS
The company news service from the London Stock Exchange




For further information, please contact:

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence / David Anderson

HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.